In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Autor: Schäfer, Alexandra, Tilahun, Kedamawit, Seder, Robert, Li, Dapeng, Nagata, Bianca M., Feldman, Jared, Janowska, Katarzyna J., Baric, Ralph S., Manne, Kartik, Caradonna, Timothy M., Cronin, Kenneth, Denny, Thomas N., Moore, Ian N., Cain, Derek W., Zhou, Tongqing, Wang, Yunfei, Stover, Erica, Alam1, S. Munir, Minai, Mahnaz, Macintyre, Andrew N., Schmidt, Aaron G., Scobey, Trevor D., Bock, Kevin W., Tse, Longping V., Deyton, Margaret, Moody, M. Anthony, Barr, Maggie, Von Holle, Tarra, Perez, Lautaro G., Lee, Esther, Sutherland, Laura L., Montefiori, David C., Edwards, Robert J., Saunders, Kevin O., McDanal, Charlene, Hernandez, Giovanna E., Mansouri, Katayoun, Parks, Robert, Lu, Xiaozhi, Hauser, Blake M., DeMarco, C. Todd, Cai, Fangping, Graham, Barney S., Wiehe, Kevin, Mascola, John R., Sempowski, Gregory D., Andersen, Hanne, Petzold, Elizabeth W., Martinez, David R., Kwong, Peter D., Gee-Lai, Victoria, Kopp, Megan, Gobeil, Sophie M. C., Stalls, Victoria, Sanzone, Aja, Rountree, Wes, Haynes, Barton F., Lewis, Mark G., Acharya1, Priyamvada, Oguin III, Thomas H., Jiang, Chuancang, Teng, I-Ting, Foulger, Andrew, Woods, Christopher W.

SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal domain (NTD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c576cb2d3f8d2c1fe7089074893bed7